Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14771565 | 0.81 | PTGS1 (0.30) | ACACBTRPV1PTGS1 | |
| SCHEMBL27697097 | 0.80 | ELANE (0.32) | ACACBTRPV1PTGS1 | |
| SCHEMBL27958479 | 0.78 | PTGS1 (0.34) | PTGS1 | |
| SCHEMBL3834654 | 0.77 | ACACB (0.35) | ACACBALDH1A1 | |
| SCHEMBL616550 | 0.76 | — | — | |
| SCHEMBL616683 | 0.76 | PTGS1 (0.30) | TRPV1PTGS1 | |
| SCHEMBL616209 | 0.76 | PTGS1 (0.30) | TRPV1PTGS1 | |
| SCHEMBL614538 | 0.74 | — | — | |
| SCHEMBL614149 | 0.72 | — | — | |
| SCHEMBL14764723 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106187942-B | Benzothiazolone compounds | 诺华股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10251868-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-10251868-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| EP-3243817-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-8933108-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933108-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2015-01-13 | — | — | US | disclosed |
| WO-2014132205-A1 | FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014033654-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033654-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2013035047-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013035047-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | SLC5A1, SLC10A1, REN | ACACB 2971/4885GSK3B 2445/4885TRPV1 363/4885 |
| US-10251868-B2 | Benzothiazolone compound | SLC5A1, SLC10A1, REN | ACACB 2971/4885GSK3B 2445/4885TRPV1 363/4885 |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | SLC5A1, SLC10A1, REN | ACACB 2971/4885GSK3B 2445/4885TRPV1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.